Download Supplemental Data - Clinical Chemistry

Supplemental Table 1. Summary of study information included in the analysis
Colorectal cancer
Gastric cancer
Cance
r type
Author
Year(Ref.)
Countr
y
Canc
er
sub
type
Samp
le
type
Conc
Chan
ge
Chen 2014,(1)
China
GC
Plasma
Fu 2014,(2)
Tsujiura 2014,(3)
Zhu 2014,(4)
Peng 2014,(5)
Kim 2013,(6)
Li 2013,(7)
Gorur 2013,(8)
Shiotani 2013,(9)
Cai 2013(10)
Xu 2013,(11)
Li 2013,(12)
Zhang 2012,(13)
Wang 2012,(14)
Zhou 2012, (15)
China
Japan
China
China
Korea
China
Turkey
Japan
China
China
China
China
China
China
GC
GC
GC
GC
GC
GC
GC
GC
GC
GC
GC
GC
GC
GC
Plasma
Plasma
Plasma
Serum
Serum
Plasma
Plasma
Serum
Plasma
Serum
Plasma
Serum
Serum
PB
Down
Up
Up
Up
Up
Up
Up
Up
Down
Up
Up
Down
Up
Down
Up
Up
Liu 2012,(16)
China
GC
Serum
Up
Valladares 2012,(17)
Konishi 2012,(18)
Spain
Japan
GC
GC
Blood
Plasma
Li 2012,(19)
China
GC
Plasma
Up
Up
Up
Down
Song 2012,(20)
China
GC
Serum
Up
Zheng 2011,(21)
Liu 2011,(22)
Zhou 2010,(23)
China
China
China
GC
GC
GC
PB
Serum
PB
Tsujiura 2010,(24)
Japan
GC
Plasma
Toiyama 2014,(25)
Japan
CRC
Serum
Wang 2014,(26)
China
CRC
Serum
Du 2014,(27)
Zanutto 2014,(28)
China
Italy
CRC
CRC
Plasma
Plasma
Up
Up
Up
Up
Down
Up
Up
Down
Up
Up
Ogata 2014,(29)
Japan
CRC
Serum
Up
Studied microRNAs
miR-122
miR-192
miR-222
miR-18a
miR-16, -25, -92a, -451, -486-5p
miR-425, -191
miR-106b, -223
miR-199a-3p
miR-195-5p
miR-106b, -21, let-7d
miR-221, -106b, -20a
miR-320a
miR-151-5p, -199a-3p
miR-375
miR-21
miR-421
miR-320c, -1182, -150*, -936, -923, -557
miR-187*, -371-5p, -378
miR-200c
miR-451, -486
miR-223, -21
miR-218
miR-221, -744, -376c, -27a, -27b, -222, -191,
let-7e
miR-21
miR-1, -20a, -27a, -34, -423
miR-17, -106a
miR-17-5p, -21, -106a, -106b
let-7a
miR-200c
miR-21, let-7g
miR-31, -92a, -181b, -203
miR-21
miR-378, -21
miR-1268, -1290, -1308, -181b, -181d, -1915, 483-5p, -638, -1224-5p
Let 7a, miR-23a, -1229, -1246, -150, -21, -223
Sample
(Cases
/Controls)
Stage (Ⅰ/Ⅱ/Ⅲ/
Ⅳ)
Assay methods
Age (year) (Cases
/Controls)
36/36
0/0/13/23
RT-qPCR
56(48-61)/59(48-61)
114/56
104/65
88/142
57/58
31/15
80/70
20/190
64/64
90/90
94/103
180/80
20/20
30/29
40/17
17/25/34/38
66/14/15/9
88/0/0/0
NA
NA
76/4/0/0
NA
NA
15/20/40/15
NA
40/29/93/18
1/1/7/4
11(I-II)/19(III-IV)
8/13/4/5
NA/NA
65.6(38-94)/NA
NA/NA
NA/43
NA/(28-43)
56.7/58.9
63.7(44-85)/29.94(18-69)
67.9/68.4
46.2±10.6/46.1±11.9
60.2(27-80)/59.1(23-80)
58.1/58.9
60.9/NA
58(36-84) /46
65.3±9.7/NA
10-Jul
2/1/3/1
52/15
56/30
9(I-II)/12/31
NA
RT-qPCR
RT-qPCR
TLDA/RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-PCR
Microarray
Microarray / RTqPCR
RT-qPCR
RT-qPCR
70/70
12/11/36/11
RT-qPCR
54 (30–77)/51(26–75)
68/68
NA
RT-qPCR
60.4±7.5/60.3±7.5
16(I-II)/37(III-IV)
29/56/48/23
NA
RT-qPCR
RT-qPCR
RT-PCR
NA/NA
60.2 ± 10.2/60.0 ± 10.4
62.3±9.8/NA
69/30
38/13/14/4
RT-qPCR
NA/NA
182/24
NA
RT-qPCR
67±10.4/64±12.9
113/89
19/43/38/13
RT-qPCR
55±7.6/57±10.4
49/49
65/70
0/42/7/0
NA
RT-qPCR
RT-qPCR
61.1±12.7/61.7±12.6
NA/NA
88/11
20/20/36/12
Microarray
52.9±7.8/51.0±9.2
101/19
27/20/42/12
Microarray
53/20
164/127
41/27
/
RT-
56.3±12.7/53.7±9.8
65.9 (42–85)/65.3(49-74)
NA/NA
(35-70)/(35-65)
qPCR
Wang 2014,(30)
China
CRC
Plasma
Up
Down
Down
Yong 2013,(31)
Malaysia
CRC
Blood
Up
miR-409-3p
miR-7, -93, -345, -25, -331-3p
miR-1274b, -130a*, -3122, -4267, -520a-3p, 548u, -92a-2*, -150, -342-3p
miR-122, -122* -1245, -18b*, -2116*, -296-5p, 3183, -409-5p, -513a-3p, -587
77/84
NA
112/50
25/32/31/24
Spain
CRC
Serum
Up
Luo 2013,(33)
Germany
CRC
Plasma
Up
Giráldez 2013,(34)
Spain
CRC
Plasma
Up
Kanaan 2013,(35)
USA
CRC
Plasma
Up
Greenberg 2013,(36)
Israel
CRC
Serum
Liu 2013,(37)
Toiyama 2013,(38)
Zhang 2013,(39)
Wang 2012,(14)
Wang 2012,(40)
Wang 2012,(41)
Kanaan 2012,(42)
Nugent 2012,(43)
Cheng 2011,(44)
Pu,2010,(45)
China
Japan
China
China
China
China
USA
Ireland
USA
China
CRC
CRC
CRC
CRC
CRC
CRC
CRC
CRC
CRC
CRC
Serum
Serum
Plasma
Serum
Serum
Plasma
Plasma
WB
Plasma
Plasma
Heneghan 2010,(46)
Ireland
CRC
Plasma
Huang 2010,(47)
China
CRC
Plasma
CRC
Plasma
Up
Zhang 2014,(49)
Hong
Kong
China
HCC
Serum
Giray 2014,(50)
Turkey
HCC
Plasma
Chiu 2013,(51)
Xie 2014,(52)
Shen 2013,(53)
Fu 2013,(54)
HCC
HCC
HCC
HCC
Serum
Serum
Plasma
Serum
HCC
Serum
Up
Tomimaru 2012,(56)
Taiwan
China
USA
China
Hong
Kong
Japan
Up
Up
Down
Up
Down
Up
Up
HCC
Plasma
Qi 2011,(57)
China
HCC
Serum
Up
Up
Down
Ng 2009,(48)
Hepatocellular cancer
Down
Up
Up
Up
Up
Up
Up
Down
Up
Down
Down
Up
Down
Up
Up
Down
Liu 2012,(55)
64/44
Microarray
64.4±9.0/61.5±9.3
30/26
0/0/30/0
Microarray
PCR
RT-qPCR
80/114
22/25/26/5
RT-qPCR
68.0±10.4/62.5±7.5
42/53
8/13/16/5
RT-qPCR
62.8/62.1
45/26
3/12/15/15
RT-qPCR
61.2(31-86)/60(29-85)
20/20
NA
RT-qPCR
55.5(24-70)/NA
200/80
186/53
78/86
32/29
114/0
90/58
30/30
63/45
74/28
103/37
18/96/64/22
45/57/43/41
36(I-II)/42(III-IV)
19(I-II)/13(III-IV)
0/27/70/20
26/25/29/10
3/4/15/4
5/22/19/16
8/14/17/35
7/38/40/18
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
Microfluidic array
RT-qPCR
RT-qPCR
RT-qPCR
57.9 (20-89)/57.5(28-89)
67.5/64
61.4/60.3
63(45-80)/46
28-82
61(21-84)/56(36-85)
60(43-76)/60(42-78)
71.2(35-90)/53.4(27-89)
54.2/55.3
58(39-84)/32(17-77)
30/63
7/13/9/1
RT-qPCR
68.8(45-88)/52.1(24-80)
100/59
27/25/38/10
RT-qPCR
61(26–84)/56(27–81)
miR-17-3p, -92
130/75
6/35/39/50
RT-qPCR
71(42–91)/69(45–85)
miR-143, -215
miR-125b-5p, -92a-3p, -122-5p
miR-223-3p
miR-130b
miR-101
miR-483-5p
miR-101
95/127
37/29/16/3
RT-qPCR
54.21±6.95/52.58±6.98
20/28
NA
RT-qPCR
60.4±2.57/49.58±2.002
20-Jun
67/30
49/49
25/20
NA
42/6/19(III-IV)
19(I-II)/30(III-IV)
6/14/5/0
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
NA/NA
51.69/37.26
61.1±11.7/61.5±11.0
NA/NA
miR-15b, -130b, -21, -183
57/59
45(I-II)/11(III-IV)
RT-qPCR
NA/NA
miR-21
miR-122, -222, -223
miR-21
126/50
67/16/43/0
RT-qPCR
63±10/62±8
70/34
8/36/20/6
RT-qPCR
49/38
miR-338-5p, -23b, -483-3p, -193a-3p, -23a
Brunet 2013,(32)
RT-qPCR
miR-18a, -29a
miR-145, -18a, -20a, -21, -29a, -92a, -106b, 133a, -143
miR-18a, -19a, -19b, -15b, -29a, -335
miR-25, -192, -431, -15b, -139-3p, -21, -331, 423-5p, -339-3p, -142-3p
miR-29c
miR-324-3p
miR-92a, -21
miR-21
miR-200c, -18a
miR-21
miR-29a
miR-601, -760
miR-21
miR-34a
miR-92
miR-221
miR-10b, -145, -155
let-7a
miR-29a, -92a
miR-25
/
RT68.1±11/64.1±7.4
Gui 2011,(58)
Xu 2011,(59)
Qu 2011,(60)
China
China
USA
HCC
HCC
HCC
Serum
Serum
Serum
Zhou 2011,(61)
China
HCC
Plasma
Up
Up
Down
Up
Down
Down
Ganepola,2014,(62)
USA
PCC
Plasma
Lung cancer
Pancreatic cancer
Up
miR-885-5p
miR-21, -122, -223
miR-195, -16, -199a
miR-194, -23b, -122, -192, -21, -801
miR-26a, -27a, -223
miR-486-5p, -18b, -1288, -486-3p, -18a, -7, 26b, -646, -1295, -301a, -106b, let-7i, -16, -20b,
-93, -106a, -17, -19b, -1468, -29b, -15b, -186, 10b, -143, -181a, -222, -221, -210, -21
miR-3184, -1909, -3154, -711, -3125, -4253, 762, -3188, -194, -193b
Up
miR-642b, -885-5p, -22
miR-196a, -196b
miR-21, -483-3p
miR-205, -210, -492, -1427
miR-744*, -1290, -628-3p, -550, -1825, -24, 134, -146a, -200c, -378, -484, -625, -22, -210
miR-221
miR-27a-3p, -16-5p, -15-5p
miR-375, -141, -548b-5p, -513a-3p
miR-222, -92a, -221
miR-20a, -21, -24, -25, -99a, -185, -191
miR-210, -16, -21, -155, -181a, -181b, -196a
miR-100a, -10
miR-18a
miR-200a, -200b
miR-21, -210, -155, -196a
Slater 2014,(63)
Abue 2014,(64)
Wang 2014,(30)
Germany
Japan
USA
PCC
PCC
PCC
Serum
Plasma
PJ
Up
Up
Up
Li 2013,(31)
USA
PCC
Serum
Up
Kawaguchi 2013,(65)
Frampton 2013,(66)
Japan
UK
PCC
PCC
Plasma
PBMC
Carlsen 2013,(67)
Denmark
PCC
Plasma
Liu R 2012,(68)
Liu J 2012,(69)
LaConti 2011,(70)
Morimura 2011,(71)
Li 2010,(72)
Wang 2009,(73)
China
China
USA
Japan
USA
USA
Serum
Plasma
Plasma
Plasma
Serum
Plasma
Krysan2014,(74)
USA
Plasma
Up
Shin 2014,(75)
Korea
PE
Yu 2014,(76)
China
Plasma
Franchina2014,(77)
Italy
PCC
PCC
PCC
PCC
PCC
PCC
NSCL
C
LADC
NSCL
C
NSCL
C
NSCL
C
Up
Up
Up
Down
Up
Up
Up
Up
Up
Up
46/24
101/89
105/71
NA
NA
NA
204/68
NA
RT-qPCR
RT-qPCR
RT-qPCR
Microarray
qPCR
11-Aug
NA
54.2/50.6
NA/NA
55(25-80)/NA
/
RT-
53/44
Microarray
64 (57-65)/46 (42-49)
Microarray
qPCR
RT-qPCR
RT-qPCR
RT-qPCR
Microarray
PCR
RT-qPCR
RT-qPCR
/
RT-
11-Nov
NA
19/10
32/30
50/19
2/7/0/10
1/8/10/13
NA
41/19
6/28/7/0
47/30
129/60
NA
NA
48/47
6/21/2021
RT-qPCR
65.49/59.53
95/81
138/68
8-Jun
36/30
45/32
49/36
NA
27/39/17/55
1/5/0/0
1/20/0/8
NA
NA
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-PCR
RT-qPCR
62.57/58.39
61.8/60.5
68.0/50.9
68(42-84)/NA
64.4 ± 10.0/44.3 ± 10.2
NA/NA
NA/(25-50)
70.6(48-89)/74.6(61-89)
NA/NA
/
RT-
65.2±10.1/43.8±11.5
67(42-84)/NA
NA/NA
miR-17, -18a, -19a, -19b, -20a, -92a
30/30
NA
Sequencing
NA/NA
Down
miR-134, -185, -22
45/42
NA
RT-qPCR
68 (33-92)/61 (22-92)
Down
miR-375
30/42/58/34
RT-qPCR
58.02±9.75/58.89±9.32
0/0/6/16
RT-qPCR
63(46-78)/NA
34(I-II)/118(III-IV)
RT-qPCR
NA/NA
60/35
NA
RT-qPCR
69.8/66.4
40/40
10/10/10/10
RT-qPCR
65.5/64.2
WB
Up
Serum
Down
Up
LC
Plasma
Up
miR-22, -24, -34a
164/164
22/27
Yang 2014,(78)
China
Cazzoli 2013,(79)
Italy
Rani 2013,(80)
Ireland
LADC
Serum
Up
Down
miR-152, -148a, -148b
miR-21
miR-378a, -379, -139-5p, -200b-5p, -151a-5p, 1974, -376a-5p, -30a-3p, -154-3p, -190b, -5025p, -629, -17, -100
miR-30c-1*, -616*, -146b-3p, -566, -550, -939
miR-339-5p, -656
Han,2013(81)
South
Korea
LADC
PE
Down
miR-198
45/42
NA
Abd-ElFattah2013,(82)
Egypt
LC
Serum
Up
miR-21, -155, -182, -197
65/37
NA
152/300
Microarray
qPCR
Microarray
qPCR
/
RT-
/
RT-
68(33-92)/61(22-92)
54.1±12.8/50.1±14.2
Breast cancer
Down
miR-10a
miR-21, -30e-5p
miR-21
miR-21,-155
miR-145
miR-942, -630, -190b, -144, let-7f, -15a, -20a, 18a, -1976, -93, -20b, -320c, -17, -652, -18b
miR-1284, -720, -1290
Serum
Down
miR-625*, -361-3p
97/30
NA
RT-qPCR
65(37-84)/40(21-66)
Serum
Up
miR-21, -205, -30d, -24
82/50
45/37(II-IV)
RT-qPCR
59/NA
Serum
Up
miR-125b
193/110
24/52/54/63
RT-qPCR
NA/NA
220/220
180/40/0/0
RT-qPCR
67.5(37-88)/67.7(33-86)
200/110
60/28/82/30
RT-qPCR
59.5±10.3/58.7±8.2
Markou2013,(83)
Greece
Wang2012,(14)
China
NSCL
C
LC
Tang,2013,(84)
China
LC
Plasma
Patnaik2012,(85)
USA
LADC
WB
Roth2012,(86)
Germany
Le 2012,(87)
China
Ma 2012,(88)
China
Heegaard,2012,(89)
USA
Chen 2012,(90)
China
Hennessey 2012,(91)
USA
Silva 2011,(92)
Spain
Roth 2011,(93)
Zheng 2011,(94)
Germany
USA
Wei 2011,(95)
China
NSCL
C
NSCL
C
NSCL
C
NSCL
C
NSCL
C
NSCL
C
NSCL
C
LC
LC
NSCL
C
NSCL
C
LC
LC
NSCL
C
NSCL
C
NSCL
C
BC
Plasma
Serum
Serum
Down
Up
Up
Up
Down
Up
Down
Up
Serum
Up
Serum
Up
Plasma
Down
Serum
Plasma
Plasma
miR-146b, -221, let-7a, -155, -17-5p, -27a, 106a
miR-29c
miR-20a, -24, -25, -145, -152, -199a-5p, -221, 222, -223, -320
37/28
NA
RT-qPCR
NA/NA
31/29
4(I-II)/27(III-IV)
RT-qPCR
61(47-78)/46
62/60
21/16/25/0
RT-qPCR
64.8/66
22/23
14/2/6/0
Microarray
70.6(50-85)/59.9(36-74)
miR-27b, -15b
55/75
33/13/7/2
RT-qPCR
68.2(48–85)/65.7(38–85)
let-7f, miR-20b, -30e-3p
78/48
NA
RT-qPCR
NA
Up
Up
miR-10b, -34a, -141, -155
miR-21, -128, -183, -155, -197, -182
35/28
6-Jun
NA
NA
RT-qPCR
RT-qPCR
55(32-71)/42(21-67)
NA
Up
miR-21
63/30
18/5/5/35
RT-qPCR
61(36-83)/57(41-75)
32/29
11/8/13(III-IV)
RT-qPCR
66.2/66.5
20/10
28/19
4/4/8/4
NA
RT-qPCR
Microarray
NA/NA
NA/NA
PB
PB
Up
Down
Up
Up
miR-21, -210
miR-486-5p
miR-21
let-7d, miR-328, -93*, -675
WB
Down
let-7a
35/30
5/1/16/13
RT-qPCR
67(48-84)/60(37-80)
Plasma
Up
Down
miR-21, -182, -210
miR-126, -486-5p
58/29
15/15/12/16
RT-qPCR
67.8/66
Serum
Up
miR-1254, -574-5p
22/31
6/14/0/0
RT-qPCR
62 (52–77)/62 (39–91)
Serum
Up
Up
Down
miR-24
miR-15a, -18a, -107, -425
miR-133a, -139-5p, -143, -145, -365
miR-186, -425, -454, -140-3p, let-7b, -483-5p, 155, -126, -146b-5p, -320, -191, -342-3p
miR-195, -486-5p, -484, -222, -574-3p, -29a
63/21
NA
RT-qPCR
58/NA
48/24
NA
RT-qPCR
58/57
miR-138
83/83
25/46/12/0
miR-29a, -181a, -223, -652
44/46
15/14/8/2
Shen(a)2011,(96)
China
Li 2011,(97)
Leidinger 2011,(98)
China
Germany
Jeong 2011,(99)
Korea
Shen(b)2010,(100)
USA
Foss 2011,(101)
USA
Sochor 2014,(102)
Czech
Kodahl 2014,(103)
Denmark
BC
Serum
Zearo 2014,(104)
Australia
BC
Serum
Plasma
Up
Waters 2014,(105)
Ireland
BC
Blood
Up
McDermott
UK
BC
Blood
Down
39/10
NA
98/25
TLDA
TLDA / RT-qPCR
Microarray / RTqPCR
RT-qPCR
58±16/60±6
57.2/57.1
59.86/44.21
2014,(106)
miR-454*, -222, -125b-2*, -1268, -200c, -15b*,
-181a-2*, -10a, -654-3p, -139-3p, -708
miR-30a, -144, -571, -93*, -487b, -1274b, 1274a, -212, -886-3p, -145, -1290, -1308, -1382*
5-Nov
NA
Up
miR-1280, -1260, -720
232/40
NA
Down
Park 2014,(107)
South
Korea
BC
WB
Up
Microarray
NA/NA
USA
Germany
Germany
Switzerla
nd
BC
BC
BC
Serum
Serum
Serum
Up
Up
Up
miR-148b, -133a
miR-373, -21, -210
miR-101, -372, -373
50/50
127/19
168/28
50(I-II)/0/0
NA
NA
Microarray
qPCR
RT-qPCR
RT-qPCR
RT-qPCR
BC
Plasma
Up
miR-373, -10b
10-Oct
NA
RT-qPCR
NA/NA
Mar-Aguilar
2013,(112)
Mexico
BC
Serum
Up
miR-10b, -21, -125b, -145, -155, -191, -382
61/10
13/14/34/0
RT-qPCR
(40-77)/NA
Cuk 2013,(113)
Germany
BC
Plasma
Up
120/60
39/55/22/2
RT-qPCR
48.6(30-77)/46.5(29-77)
Chan 2013,(114)
Singapor
e
BC
Serum
32/22
NA
RT-qPCR
50±13/47±6
Wang 2013,(115)
Zeng 2013,(116)
China
China
BC
BC
Serum
Plasma
46/58
100/64
NA
45/32/10/7
48.3(30-79)/52.0
51.4(30-84)/48.9(20-72)
Ng 2013,(117)
Hong
Kong
BC
Plasma
185/145
50/61/27/5
RT-qPCR
RT-qPCR
Microarray
Microarray
qPCR
Si 2013,(118)
China
BC
Serum
100/20
NA
RT-qPCR
NA/NA
Liu 2013,(119)
China
BC
Serum
20/10
3/10/7/0
RT-qPCR
NA/NA
Gao 2013,(120)
Wang 2012,(14)
Sun 2012,(121)
Jung 2012,(122)
van Schooneveld
2012,(123)
Schwarzenbach
2012,(124)
Wang 2012,(125)
Nugent 2012,(43)
China
China
China
USA
BC
BC
BC
BC
89/55
50/29
103/55
27/28
21/28/9/31
48(I-II)/2(III-IV)
29/36/30/8
NA
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
56(29-80)/50(28-65)
53(28–89)/46
53 (21-79)/51 (36-78)
52(21-70)/53.5(22-71)
Belgium
Shen 2014,(108)
Müller 2014,(109)
Eichelser 2014,(110)
Chen 2013,(111)
/
RT-
NA/NA
NA/NA
NA/NA
59(30-85)/NA
Serum
Serum
Serum
Plasma
Down
Up
Down
Up
Up
Down
Down
Up
Down
Up
Up
Up
Up
Up
miR-801, -127-3p, -376a, -652, -148b, -376c, 409-3p
let-7i,et-7b,miR-1, -133b, -133a, -92a, -10b, 486-5p, -423-5p, -7, -20a, -185, -16, -214, l, 144, -16-2*, -320a, -93
miR-223, -338-3p
miR-182
miR-30a
miR-27a, -150, -191, -200c, -210
miR-16, -21, -451
miR-145
miR-92a
miR-21
miR-205
miR-155
miR-21
miR-21
miR-155
miR-210, -21, -126, -29a
BC
Serum
Down
miR-411, -299-5p
75/20
19/14/22/20
RT-qPCR
NA/NA
Germany
BC
Serum
Up
miR-20a, -21, -214
102/53
NA
RT-qPCR
60(30-82)/50(20-79)
China
Ireland
BC
BC
Serum
WB
Up
Down
56/10
19/45
0/35/21/0
1/12/4/1
RT-qPCR
RT-qPCR
55(36-78)/NA
58(48-79)/53.4(27-89)
Schrauder 2012,(126)
Germany
BC
WB
Up
48/57
NA
Microarray
62 (34-89)/58
Guo 2012,(127)
China
BC
Serum
Down
miR-125b, -155, -10b
miR-34a
miR-4306, -425, -1323, -335, -497, -106b, -922,
-516b, -202, let-7a*
miR-718, -625*, -1471, -193a-3p, -182, -1915, 564, -107, -2355, -3186-3p, -24, -3130-3p, 526a, -1469, -874
miR-181a
152/75
40/79/13/16
RT-qPCR
50.38(25-83)/48.4(22-60)
Up
/
RT-
60(36-84)/61(40-85)
Cervical
cancer
Prostate cancer
Hu 2012,(128)
Wu 2012,(129)
Zhao 2012,(130)
Asaga 2011,(131)
Heneghan 2010,(46)
Roth 2010,(132)
China
China
China
USA
Ireland
Germany
BC
BC
BC
BC
BC
BC
Serum
Serum
Serum
Serum
Plasma
Serum
Up
Up
Up
Up
Up
Up
Zhao 2010,(133)
USA
BC
Plasma
Up
Chen 2013,(134)
China
CC
Serum
Up
Zhao 2013,(135)
Yu 2012,(136)
Li 2014,(137)
Wang 2014,(138)
Farina 2014,(139)
China
China
China
China
USA
CC
CC
CC
CC
PC
Serum
Serum
Serum
Serum
Serum
Cheng 2013,(140)
USA
PC
Serum
Up
Down
Down
Up
Up
Up
Down
Up
Up
Down
Up
Up
Nguyen 2013,(141)
USA
PC
Serum
Selth 2012,(142)
Shen 2012,(143)
Australia
USA
PC
PC
Serum
Plasma
Bryant 2012,(144)
USA
PC
Plasma
Chen 2012,(145)
China
PC
Plasma
Heneghan 2012,(46)
Ireland
PC
Plasma
Gonzales 2011,(146)
Brase 2011,(147)
Mitchell 2008,(148)
USA
USA
USA
PC
PC
PC
Plasma
Plasma
Serum
Up
Down
Down
Up
Down
Up
Up
Up
Up
miR-16, -25, -222, -324-3p
miR-222
miR-10b
miR-21
miR-195, let-7a
miR-155, -10b, -34a
miR-595, -589, -504, -518b, -483-5p, -425*, 493, -187, -431*, -1231
miR-668, -377, -410, -922, -155, -340*, -432, 574-3p, -148a, -181a, -1275, -1304, -151-5p
miR-1246, -20a, -2392, -3147, -3162-5p, -4484,
-4667-5p
miR-20a, -203
miR-218
miR-1, -2
miR-646
miR-21-5p, -93-5p
miR-100, -148a, -425-5p
miR-222
miR-141, -200a, -200c, -210, -375
miR-375,-378*,-141
miR-409-3p
miR-375, -141, -298, -346
miR-20a, -21, -145
miR-107, -130b, -141, -2110, -301a, -326, -3313p, -432, -484, -574-3p, -625*
miR-181a-2*
let-7e, let-7c, -30c
miR-1285, -622
miR-145, -155
let-7a
miR-141
miR-375, -141
miR-141, -100, -125b, -143, -296
76/76
50/50
122/59
102/20
83/63
89/29
24/36/16/0
50(I-II)
22/48/20/22
31/26/22/23
14/35/18/6
NA
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
52.99/49.16
55/53
52(26-77)/50(28-72)
NA/NA
55.1(30-88)/52.1(24-80)
56(31-82)/NA
20/20
20(I-II)
Microarray
56/57
40/20
NA
RT-qPCR
NA/NA
80/20
90/50
112/85
15-Oct
6-Oct
0/80（I-II/0/0)
62/18/6/4
NA
0/9/1/0/0
NA
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
49(25-69)/45(33-57)
51.0(36-70)/NA
47.86/NA
51(34-78)/28.8(24-34)
NA/NA
25/25
NA
TLDA
NA/NA
TLDA / RT-qPCR
84/0
NR
RT-qPCR
60 (53–69)
25/25
82/0
NA
0/82(Ⅱ-Ⅲ)/0
RT-qPCR
RT-qPCR
73.5(45-86)/NA
61.2
78/28
NA
RT-qPCR
70/63
80/54
NA
RT-qPCR
73(57-94)/73(54-84)
20/63
1/10/9/0
RT-qPCR
60.6(50-68)/52.1(24-80)
21/0
137/0
25/25
NR
NR
NA
RT-qPCR
TLDA and RT-qPCR
RT-qPCR
60-77
63.1
NA/NA
Abbreviations: NSCLC, Non-small cell lung cancer; LADC, Lung adenocarcinoma; LC, Lung cancer; HCC, Hepatocellular cancer; GC, Gastric cancer; PCC, Pancreatic cancer; CRC, Colorectal
cancer; PC, Prostate cancer; BC, Breast cancer; CC,Cervical cancer; NA, not available; PE, Pleural effusion; WB, Whole blood; PJ, Pancreatic juice; PBMC,peripheral blood mononuclear cell;
PB, peripheral blood; TLDA, TaqMan low density arrays.
Supplemental Figure 1. Number of patients involved in each sample type (A) and number of
dysregulated miRNA identified in each cancer type (B).
A)
B)
Supplemental References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q, et al. Plasma mir-122 and mir-192 as potential novel
biomarkers for the early detection of distant metastasis of gastric cancer. Oncology reports 2014;31:186370.
Fu Z, Qian F, Yang X, Jiang H, Chen Y, Liu S. Circulating mir-222 in plasma and its potential diagnostic
and prognostic value in gastric cancer. Medical Oncology 2014;31:1-8.
Tsujiura M, Komatsu S, Ichikawa D, Shiozaki A, Konishi H, Takeshita H, et al. Circulating mir-18a in
plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer
2014:1-9.
Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microrna panel in plasma was identified as
potential biomarker for early detection of gastric cancer. British journal of cancer 2014;110:2291-9.
Peng W-Z, Ma R, Wang F, Yu J, Liu Z-B. Role of mir-191/425 cluster in tumorigenesis and diagnosis of
gastric cancer. International journal of molecular sciences 2014;15:4031-48.
Kim SY, Jeon TY, Choi CI, Kim DH, Kim DH, Kim GH, et al. Validation of circulating mirna biomarkers
for predicting lymph node metastasis in gastric cancer. The Journal of Molecular Diagnostics 2013;15:6619.
Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, Zhu ZG. Mirna‐199a‐3p: A potential circulating diagnostic
biomarker for early gastric cancer. Journal of surgical oncology 2013;108:89-92.
Gorur A, Fidanci SB, Unal ND, Ayaz L, Akbayir S, Yaroglu HY, et al. Determination of plasma microrna
for early detection of gastric cancer. Molecular biology reports 2013;40:2091-6.
Shiotani A, Murao T, Kimura Y, Matsumoto H, Kamada T, Kusunoki H, et al. Identification of serum
mirnas as novel non-invasive biomarkers for detection of high risk for early gastric cancer. British journal
of cancer 2013;109:2323-30.
Cai H, Yuan Y, Hao Y-F, Guo T-K, Wei X, Zhang Y-M. Plasma micrornas serve as novel potential
biomarkers for early detection of gastric cancer. Medical Oncology 2013;30:1-7.
Xu Q, Dong Q-G, Sun L-p, He C-y, Yuan Y. Expression of serum mir-20a-5p, let-7a, and mir-320a and
their correlations with pepsinogen in atrophic gastritis and gastric cancer: A case–control study. BMC
clinical pathology 2013;13:11.
Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. Microrna array analysis finds
elevated serum mir-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy
and disease controls. Clinical Cancer Research 2013;19:3600-10.
Zhang W-H, Gui J-H, Wang C-Z, Chang Q, Xu S-P, Cai C-H, et al. The identification of mir-375 as a
potential biomarker in distal gastric adenocarcinoma. Oncology Research Featuring Preclinical and Clinical
Cancer Therapeutics 2012;20:139-47.
Wang B, Zhang Q. The expression and clinical significance of circulating microrna-21 in serum of five
solid tumors. Journal of cancer research and clinical oncology 2012;138:1659-66.
Zhou H, Xiao B, Zhou F, Deng H, Zhang X, Lou Y, et al. Mir-421 is a functional marker of circulating
tumor cells in gastric cancer patients. Biomarkers 2012;17:104-10.
Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microrna profiles identify mir-378 as
a serum biomarker for early detection of gastric cancer. Cancer letters 2012;316:196-203.
Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, et al.
Circulating mir-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med
2012;10:186.
Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, et al. Detection of gastric cancerassociated micrornas on microrna microarray comparing pre-and post-operative plasma. British journal of
cancer 2012;106:740-7.
Li B-s, Zhao Y-l, Guo G, Li W, Zhu E-d, Luo X, et al. Plasma micrornas, mir-223, mir-21 and mir-218, as
novel potential biomarkers for gastric cancer detection. PloS one 2012;7:e41629.
Song M-y, Pan K-f, Su H-j, Zhang L, Ma J-l, Li J-y, et al. Identification of serum micrornas as novel noninvasive biomarkers for early detection of gastric cancer. PloS one 2012;7:e33608.
Zheng Y, Cui L, Sun W, Zhou H, Yuan X, Huo M, et al. Microrna-21 is a new marker of circulating tumor
cells in gastric cancer patients. Cancer Biomarkers 2011;10:71-7.
Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microrna signature identified from genomewide serum microrna expression profiling serves as a fingerprint for gastric cancer diagnosis. European
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
journal of cancer 2011;47:784-91.
Zhou H, Guo J-M, Lou Y-R, Zhang X-J, Zhong F-D, Jiang Z, et al. Detection of circulating tumor cells in
peripheral blood from patients with gastric cancer using microrna as a marker. Journal of molecular
medicine 2010;88:709-17.
Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating micrornas in
plasma of patients with gastric cancers. British journal of cancer 2010;102:1174-9.
Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum mir-200c is a novel
prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Annals of surgery
2014;259:735-43.
Wang J, Huang S-k, Zhao M, Yang M, Zhong J-l, Gu Y-y, et al. Identification of a circulating microrna
signature for colorectal cancer detection. PloS one 2014;9:e87451.
Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M, et al. Clinical potential role of circulating micrornas in early
diagnosis of colorectal cancer patients. Carcinogenesis 2014:bgu189.
Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, Perrone F, et al. Circulating mir-378 in
plasma: A reliable, haemolysis-independent biomarker for colorectal cancer. British journal of cancer
2014;110:1001-7.
Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal
micrornas as biomarkers of colon cancer. PloS one 2014;9:e92921.
Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, et al. A plasma microrna panel for early detection of colorectal
cancer. International Journal of Cancer 2014.
Yong FL, Law CW, Wang CW. Potentiality of a triple microrna classifier: Mir-193a-3p, mir-23a and mir338-5p for early detection of colorectal cancer. BMC cancer 2013;13:280.
Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. Microrna expression profile in stage iii
colorectal cancer: Circulating mir-18a and mir-29a as promising biomarkers. Oncology reports
2013;30:320-6.
Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma micrornas for early
detection of colorectal cancer. PloS one 2013;8:e62880.
Giráldez MD, Lozano JJ, Ramírez G, Hijona E, Bujanda L, Castells A, Gironella M. Circulating micrornas
as biomarkers of colorectal cancer: Results from a genome-wide profiling and validation study. Clinical
Gastroenterology and Hepatology 2013;11:681-8. e3.
Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, et al. A plasma microrna panel for
detection of colorectal adenomas: A step toward more precise screening for colorectal cancer. Annals of
surgery 2013;258:400-8.
Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, et al. A comparative
analysis of total serum mirna profiles identifies novel signature that is highly indicative of metastatic
melanoma: A pilot study. Biomarkers 2013;18:502-8.
Liu G-H, Zhou Z-G, Chen R, Wang M-J, Li Y, Sun X-F. Serum mir-21 and mir-92a as biomarkers in the
diagnosis and prognosis of colorectal cancer. Tumor Biology 2013;34:2175-81.
Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum mir-21 as a diagnostic and
prognostic biomarker in colorectal cancer. Journal of the National Cancer Institute 2013;105:849-59.
Zhang G-J, Zhou T, Liu Z-L, Tian H-P, Xia S-S. Plasma mir‑200c and mir‑18a as potential biomarkers for
the detection of colorectal carcinoma. Molecular and clinical oncology 2013;1:379-84.
Wang L-g, Gu J. Serum microrna-29a is a promising novel marker for early detection of colorectal liver
metastasis. Cancer epidemiology 2012;36:e61-e7.
Wang Y, Xie CL, Lu L, Fu DL, Zheng GQ. Chinese herbal medicine paratherapy for parkinson's disease: A
meta-analysis of 19 randomized controlled trials. Evid Based Complement Alternat Med
2012;2012:534861.
Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S. Plasma mir-21: A
potential diagnostic marker of colorectal cancer. Annals of surgery 2012;256:544-51.
Nugent M, Miller N, Kerin M. Circulating mir‐34a levels are reduced in colorectal cancer. Journal of
surgical oncology 2012;106:947-52.
Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma mir-141 is a
novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS one 2011;6:e17745.
Pu Xx, Huang Gl, Guo Hq, Guo Cc, Li H, Ye S, et al. Circulating mir‐221 directly amplified from plasma
is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
Journal of gastroenterology and hepatology 2010;25:1674-80.
Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic mirna-195 differentiates breast cancer
from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The
oncologist 2010;15:673-82.
Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma micrornas are promising novel biomarkers for
early detection of colorectal cancer. International Journal of Cancer 2010;127:118-26.
Ng EK, Chong WW, Lam EK, Shin VY, Yu J, Poon TC, et al. Differential expression of micrornas in
plasma of colorectal cancer patients: A potential marker for colorectal cancer screening. Gut 2009.
Zhang Z-q, Meng H, Wang N, Liang L-n, Liu L-n, Lu S-m, Luan Y. Serum microrna 143 and microrna 215
as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagnostic
pathology 2014;9:135.
Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, et al. Profiles of serum micrornas; mir125b-5p and mir223-3p serve as novel biomarkers for hbv-positive hepatocellular carcinoma. Molecular
biology reports 2014:1-7.
Chiu L-Y, Kishnani PS, Chuang T-P, Tang C-Y, Liu C-Y, Bali D, et al. Identification of differentially
expressed micrornas in human hepatocellular adenoma associated with type i glycogen storage disease: A
potential utility as biomarkers. Journal of gastroenterology 2013:1-11.
Xie Y, Yao Q, Butt AM, Guo J, Tian Z, Bao X, et al. Expression profiling of serum microrna-101 in hbvassociated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer biology & therapy
2014;15:1248-55.
Shen J, Wang A, Wang Q, Gurvich I, Siegel AB, Remotti H, Santella RM. Exploration of genome-wide
circulating microrna in hepatocellular carcinoma: Mir-483-5p as a potential biomarker. Cancer
Epidemiology Biomarkers & Prevention 2013;22:2364-73.
Fu Y, Wei X, Tang C, Li J, Liu R, Shen A, Wu Z. Circulating microrna‑101 as a potential biomarker for
hepatitis b virus‑related hepatocellular carcinoma. Oncology letters 2013;6:1811-5.
Liu AM, Yao T-J, Wang W, Wong K-F, Lee NP, Fan ST, et al. Circulating mir-15b and mir-130b in serum as
potential markers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ open 2012;2.
Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating< i> microrna21</i> as a novel biomarker for hepatocellular carcinoma. Journal of hepatology 2012;56:167-75.
Qi P, Cheng S-q, Wang H, Li N, Chen Y-f, Gao C-f. Serum micrornas as biomarkers for hepatocellular
carcinoma in chinese patients with chronic hepatitis b virus infection. PloS one 2011;6:e28486.
Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microrna characterization identifies mir-8855p as a potential marker for detecting liver pathologies. Clinical science 2011;120:183-93.
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating micrornas, mir‐21, mir‐122, and mir‐
223, in patients with hepatocellular carcinoma or chronic hepatitis. Molecular carcinogenesis 2011;50:13642.
Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating micrornas as biomarkers for hepatocellular
carcinoma. Journal of clinical gastroenterology 2011;45:355-60.
Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microrna panel to diagnose hepatitis b virus–
related hepatocellular carcinoma. Journal of Clinical Oncology 2011;29:4781-8.
Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microrna
biomarker panel for early diagnosis of pancreatic cancer. World journal of gastrointestinal oncology
2014;6:22.
Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Klöppel G, et al. Microrna-196a and -196b
as potential biomarkers for the early detection of familial pancreatic cancer. Translational Oncology
2014;7:464-71.
Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, et al. Circulating mir-483-3p and mir21 is highly expressed in plasma of pancreatic cancer. International journal of oncology 2015;46:539-47.
Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, et al. Clinical impact of
circulating mir-221 in plasma of patients with pancreatic cancer. British journal of cancer 2013;108:361-9.
Frampton AE, Fletcher CE, Gall TM, Castellano L, Bevan CL, Stebbing J, Krell J. Circulating peripheral
blood mononuclear cells exhibit altered mirna expression patterns in pancreatic cancer. Expert review of
molecular diagnostics 2013;13:425-30.
Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OBS, Heegaard NH. Cell-free plasma microrna in
pancreatic ductal adenocarcinoma and disease controls. Pancreas 2013;42:1107-13.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microrna expression profile as a biomarker in
the diagnosis and prognosis of pancreatic cancer. Clinical chemistry 2012;58:610-8.
Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, et al. Combination of plasma micrornas with serum ca19‐9 for
early detection of pancreatic cancer. International Journal of Cancer 2012;131:683-91.
LaConti JJ, Shivapurkar N, Preet A, Mays AD, Peran I, Kim SE, et al. Tissue and serum micrornas in the
krasg12d transgenic animal model and in patients with pancreatic cancer. PloS one 2011;6:e20687.
Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, et al. Novel diagnostic value of
circulating mir-18a in plasma of patients with pancreatic cancer. British journal of cancer 2011;105:173340.
Li A, Omura N, Hong S-M, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence
sip1 and hypomethylate and overexpress mir-200a/200b in association with elevated circulating mir-200a
and mir-200b levels. Cancer research 2010;70:5226-37.
Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. Micrornas in plasma of pancreatic ductal
adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer prevention research
2009;2:807-13.
Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, et al. Pge2-driven expression of c-myc
and oncomir-17-92 contributes to apoptosis resistance in nsclc. Molecular Cancer Research 2014;12:765-74.
Shin YM, Yun J, Lee O-J, Han H-S, Lim S-N, An JY, et al. Diagnostic value of circulating extracellular
mir-134, mir-185, and mir-22 levels in lung adenocarcinoma-associated malignant pleural effusion. Cancer
Research and Treatment 2014;46:178-85.
Yu H, Jiang L, Sun C, Guo L, Lin M, Huang J, Zhu L. Decreased circulating mir-375: A potential
biomarker for patients with non-small-cell lung cancer. Gene 2014;534:60-5.
Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, et al. Circulating mir‐22, mir‐24
and mir‐34a as novel predictive biomarkers to pemetrexed‐based chemotherapy in advanced non‐small
cell lung cancer. Journal of cellular physiology 2014;229:97-9.
Yang J-s, Li B-j, Lu H-w, Chen Y, Lu C, Zhu R-x, et al. Serum mir-152, mir-148a, mir-148b, and mir-21 as
novel biomarkers in non-small cell lung cancer screening. Tumor Biology 2014:1-8.
Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, Pass HI. Micrornas derived from
circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. Journal of
Thoracic Oncology 2013;8:1156-62.
Rani S, Gately K, Crown J, O’Byrne K, O’Driscoll L. Global analysis of serum micrornas as potential
biomarkers for lung adenocarcinoma. Cancer Biol Ther 2013;14:1104-12.
Han HS, Yun J, Lim Sn, Han JH, Lee KH, Kim ST, et al. Downregulation of cell‐free mir‐198 as a
diagnostic biomarker for lung adenocarcinoma ‐associated malignant pleural effusion. International
Journal of Cancer 2013;133:645-52.
Abd-El-Fattah AA, Sadik NAH, Shaker OG, Aboulftouh ML. Differential micrornas expression in serum of
patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell biochemistry and biophysics
2013;67:875-84.
Markou A, Sourvinou I, Vorkas P, Yousef G, Lianidou E. Clinical evaluation of microrna expression
profiling in non small cell lung cancer. Lung Cancer 2013;81:388-96.
Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma micrornas as novel
noninvasive biomarkers for early detection of lung cancer. European Journal of Cancer Prevention
2013;22:540-8.
Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. Microrna expression profiles
of whole blood in lung adenocarcinoma. PloS one 2012;7:e46045.
Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating
mir-361-3p and mir-625* as blood-based markers for discriminating malignant from benign lung tumors.
PloS one 2012;7:e38248.
Le H-B, Zhu W-Y, Chen D-D, He J-Y, Huang Y-Y, Liu X-G, Zhang Y-K. Evaluation of dynamic change of
serum mir-21 and mir-24 in pre-and post-operative lung carcinoma patients. Medical Oncology
2012;29:3190-7.
Yuxia M, Zhennan T, Wei Z. Circulating mir-125b is a novel biomarker for screening non-small-cell lung
cancer and predicts poor prognosis. Journal of cancer research and clinical oncology 2012;138:2045-50.
Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro‐rna
expression profiles in early stage nonsmall cell lung cancer. International Journal of Cancer
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
2012;130:1378-86.
Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, et al. Identification of ten serum micrornas from a
genome‐wide serum microrna expression profile as novel noninvasive biomarkers for nonsmall cell lung
cancer diagnosis. International Journal of Cancer 2012;130:1620-8.
Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, et al. Serum microrna
biomarkers for detection of non-small cell lung cancer. PloS one 2012;7:e32307.
Silva J, García V, Zaballos A, Provencio M, Lombardía L, Almonacid L, et al. Vesicle-related micrornas in
plasma of nonsmall cell lung cancer patients and correlation with survival. European Respiratory Journal
2011;37:617-23.
Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase
activity in the peripheral blood as potential diagnostic tools in lung cancer. Molecular oncology
2011;5:281-91.
Zheng D, Haddadin S, Wang Y, Gu L-Q, Perry MC, Freter CE, Wang MX. Plasma micrornas as novel
biomarkers for early detection of lung cancer. International journal of clinical and experimental pathology
2011;4:575.
Wei J, Gao W, Zhu C-J, Liu Y-Q, Mei Z, Cheng T, Shu Y-Q. Identification of plasma microrna-21 as a
biomarker for early detection and chemosensitivity of non–small cell lung cancer. Chinese journal of cancer
2011;30:407.
Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, et al. Diagnosis of lung cancer in individuals with solitary
pulmonary nodules by plasma microrna biomarkers. BMC cancer 2011;11:374.
Li Y, Li W, Ouyang Q, Hu S, Tang J. Detection of lung cancer with blood microrna-21 expression levels in
chinese population. Oncology letters 2011;2:991.
Leidinger P, Keller A, Borries A, Huwer H, Rohling M, Huebers J, et al. Specific peripheral mirna profiles
for distinguishing lung cancer from copd. Lung Cancer 2011;74:41-7.
Jeong HC, Kim EK, Lee JH, Yoo HN, Kim JK. Aberrant expression of let-7a mirna in the blood of nonsmall cell lung cancer patients. Molecular medicine reports 2011;4:383-7.
Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma micrornas as potential biomarkers for
non-small-cell lung cancer. Laboratory investigation 2010;91:579-87.
Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. Mir-1254 and mir-574-5p: Serum-based
microrna biomarkers for early-stage non-small cell lung cancer. Journal of Thoracic Oncology 2011;6:4828.
Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, et al. Oncogenic micrornas: Mir-155, mir19a, mir-181b, and mir-24 enable monitoring of early breast cancer in serum. BMC cancer 2014;14:448.
Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ. Novel circulating microrna
signature as a potential non-invasive multi-marker test in er-positive early-stage breast cancer: A case
control study. Molecular oncology 2014.
Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG, Soon PS. Microrna-484 is more highly
expressed in serum of early breast cancer patients compared to healthy volunteers. BMC cancer
2014;14:200.
Waters PS, Dwyer RM, Brougham C, Glynn CL, Wall D, Hyland P, et al. Impact of tumour epithelial
subtype on circulating micrornas in breast cancer patients. PloS one 2014;9:e90605.
McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ. Identification and
validation of oncologic mirna biomarkers for luminal a-like breast cancer. PloS one 2014;9:e87032.
Park IH, Kang JH, Lee KS, Nam S, Ro J, Kim J-H. Identification and clinical implications of circulating
micrornas for estrogen receptor-positive breast cancer. Tumor Biology 2014;35:12173-80.
Shen J, Hu Q, Schrauder M, Yan L, Wang D, Medico L, et al. Circulating mir-148b and mir-133a as
biomarkers for breast cancer detection. Oncotarget 2014;5:5284.
Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, et al. Changes in serum levels of mir21, mir-210, and mir-373 in her2-positive breast cancer patients undergoing neoadjuvant therapy: A
translational research project within the geparquinto trial. Breast cancer research and treatment
2014;147:61-8.
Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H. Increased
serum levels of circulating exosomal microrna-373 in receptor-negative breast cancer patients. Oncotarget
2014;5:9650.
Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating mirna-10b and mirna-373 in
detecting lymph node metastasis of breast cancer: Potential biomarkers. Tumor Biology 2013;34:455-62.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino-Silva PK, Santuario-Facio SK, RuizFlores P, et al. Serum circulating microrna profiling for identification of potential breast cancer biomarkers.
Disease markers 2013;34:163-9.
Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J, et al. Plasma microrna panel for minimally
invasive detection of breast cancer. PloS one 2013;8:e76729.
Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microrna
signatures for breast cancer detection. Clinical Cancer Research 2013;19:4477-87.
Wang PY, Gong HT, Li BF, Lv CL, Wang HT, Zhou HH, et al. Higher expression of circulating mir‑182 as
a novel biomarker for breast cancer. Oncology letters 2013;6:1681-6.
Zeng R-c, Zhang W, Yan X-q, Ye Z-q, Chen E-d, Huang D-p, et al. Down-regulation of mirna-30a in human
plasma is a novel marker for breast cancer. Medical Oncology 2013;30:1-8.
Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, et al. Circulating micrornas as specific biomarkers for
breast cancer detection. PloS one 2013;8:e53141.
Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C. Circulating microrna-92a and microrna-21 as novel
minimally invasive biomarkers for primary breast cancer. Journal of cancer research and clinical oncology
2013;139:223-9.
Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of mir-205 and mir-155 expression in the blood of
breast cancer patients. Chinese Journal of Cancer Research 2013;25:46.
Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum mir-21 in breast cancer compared with
ca153 and cea. Chinese Journal of Cancer Research 2013;25:743.
Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J. Serum microrna-155 as a potential biomarker to track
disease in breast cancer. PloS one 2012;7:e47003.
Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microrna 210 levels correlate
with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012;118:2603-14.
van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, et al.
Expression profiling of cancerous and normal breast tissues identifies micrornas that are differentially
expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer
Research 2012;14:R34.
Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K. Diagnostic potential of ptentargeting mir-214 in the blood of breast cancer patients. Breast cancer research and treatment
2012;134:933-41.
Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H. Circulating mir-125b as a marker predicting
chemoresistance in breast cancer. PloS one 2012;7:e34210.
Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, et al. Circulating
micro-rnas as potential blood-based markers for early stage breast cancer detection. PloS one
2012;7:e29770.
Guo L-J, Zhang Q-Y. Decreased serum mir-181a is a potential new tool for breast cancer screening. Int J
Mol Med 2012;30:680-6.
Hu Z, Dong J, Wang L-E, Ma H, Liu J, Zhao Y, et al. Serum microrna profiling and breast cancer risk: The
use of mir-484/191 as endogenous controls. Carcinogenesis 2012:bgs030.
Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide micrornas for breast cancer detection.
Clinica chimica acta 2012;413:1058-65.
Zhao F, Hu G, Wang X, Zhang X, Zhang Y, Yu Z. Serum overexpression of microrna-10b in patients with
bone metastatic primary breast cancer. Journal of International Medical Research 2012;40:859-66.
Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microrna-21
concentrations in early and advanced breast cancer. Clinical chemistry 2011;57:84-91.
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating micrornas as blood-based
markers for patients with primary and metastatic breast cancer. Breast Cancer Research 2010;12:R90.
Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating mirnas as potential
biomarkers of early stage breast cancer. PloS one 2010;5:e13735.
Chen J, Yao D, Li Y, Chen H, He C, Ding N, et al. Serum microrna expression levels can predict lymph
node metastasis in patients with early-stage cervical squamous cell carcinoma. International journal of
molecular medicine 2013;32:557-67.
Zhao S, Yao D, Chen J, Ding N. Circulating mirna-20a and mirna-203 for screening lymph node metastasis
in early stage cervical cancer. Genetic testing and molecular biomarkers 2013;17:631-6.
Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microrna-218 was reduced in cervical cancer
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
and correlated with tumor invasion. Journal of cancer research and clinical oncology 2012;138:671-4.
Juan L, Tong H-l, Zhang P, Guo G, Wang Z, Wen X, et al. Identification and characterization of novel
serum microrna candidates from deep sequencing in cervical cancer patients. Scientific reports 2014;4.
Wang W-T, Zhao Y-N, Yan J-X, Weng M-Y, Wang Y, Chen Y-Q, Hong S-J. Differentially expressed
micrornas in the serum of cervical squamous cell carcinoma patients before and after surgery. Journal of
hematology & oncology 2014;7:6.
Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL, Lian JB. Standardizing analysis of
circulating microrna: Clinical and biological relevance. Journal of cellular biochemistry 2014;115:805-11.
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, et al. Circulating microrna profiling
identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PloS
one 2013;8:e69239.
Nguyen HCN, Xie W, Yang M, Hsieh CL, Drouin S, Lee GSM, Kantoff PW. Expression differences of
circulating micrornas in metastatic castration resistant prostate cancer and low‐risk, localized prostate
cancer. The Prostate 2013;73:346-54.
Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating
micrornas associated with human prostate cancer using a mouse model of disease. International Journal of
Cancer 2012;131:652-61.
Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM. Dysregulation of
circulating micrornas and prediction of aggressive prostate cancer. The Prostate 2012;72:1469-77.
Bryant R, Pawlowski T, Catto J, Marsden G, Vessella R, Rhees B, et al. Changes in circulating microrna
levels associated with prostate cancer. British journal of cancer 2012;106:768-74.
Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J. A panel of five circulating micrornas as
potential biomarkers for prostate cancer. The Prostate 2012;72:1443-52.
Gonzales JC, Fink LM, Goodman Jr OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of
circulating microrna 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for
determining treatment response in patients with metastatic prostate cancer. Clinical genitourinary cancer
2011;9:39-45.
Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating mirnas are correlated
with tumor progression in prostate cancer. International Journal of Cancer 2011;128:608-16.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating
micrornas as stable blood-based markers for cancer detection. Proceedings of the National Academy of
Sciences 2008;105:10513-8.